Merck Aktie
| 97,43USD | 0,89USD | 0,92% |
WKN DE: A0YD8Q / ISIN: US58933Y1055
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,90 |
| The Vanguard Group, Inc. | 9,66 |
| Vanguard Group, Inc. (Subfiler) | 9,38 |
| State Street Corp. | 4,70 |
| Vanguard Total Stock Market ETF | 3,17 |
| BlackRock Fund Advisors | 3,01 |
| Wellington Management Co. LLP (Wellington Breakout) | 2,85 |
| Vanguard 500 Index Fund | 2,62 |
| Geode Capital Management LLC | 2,33 |
| BlackRock Institutional Trust Co. NA | 2,24 |
| Fidelity Management & Research Co. LLC | 1,47 |
| Norges Bank (13F) | 1,33 |
| Fidelity 500 Index Fund | 1,23 |
| SPDR S&P 500 ETF Trust | 1,21 |
| iShares Core S&P 500 ETF | 1,11 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 71 000 | 74 000 | 68 000 | 69 000 | 72 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,66 | 0,65 | 0,72 | 0,85 | 0,83 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 27 483 | 27 764 | 30 266 | 35 722 | 32 168 |
| Summe Anlagevermögen | 56 914 | 63 824 | 75 428 | 73 438 | 74 507 |
| Summe Aktiva | 84 397 | 91 588 | 105 694 | 109 160 | 106 675 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 27 350 | 33 453 | 34 631 | 31 985 | 36 268 |
| Summe Fremdkapital | 58 396 | 66 184 | 67 437 | 63 102 | 69 040 |
| Summe Eigenkapital | 26 001 | 25 404 | 38 257 | 46 058 | 37 635 |
| Summe Passiva | 84 397 | 91 588 | 105 694 | 109 160 | 106 675 |
Adresse
| 126 East Lincoln Avenue, 07065 Rahway | |
| Telefon | +1 (908) 740-4000 |
| Internet | http://www.merck.com |
Management
|
Allan Gabor
President-Asian-Pacific-BioPharma Business |
|
Andre Musto
SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
|
Betty D. Larson
Chief Human Resources Officer & Executive VP |
|
Brooke Hinkson
Executive Director-Global Clinical Data Standards |
|
Carol Bowden
Med Aff. Dir, Cardiovascular Metabolism, NorCal |
|
Caroline A. Litchfield
Chief Financial Officer & Executive Vice President |
|
Chirfi Guindo
Chief Marketing Officer-Human Health & SVP |
|
Christine E. Seidman
Independent Director |
|
Dalton E. Smart
Senior Vice President-Finance & Global Controller |
|
Dave Williams
Chief Information & Digital Officer |
|
Dean Y. Li
EVP & President-Merck Research Laboratories |
|
Denise Williams
Vice President |
|
Douglas M. Baker
Independent Director |
|
Eric H. Rubin
Senior VP-Global Clinical Oncology |
|
Fiona Hamilton Marshall
Senior VP & Global Head-Discovery Sciences |
|
Inge G. Thulin
Independent Director |
|
James Matteucci
Associate Director-State Government Affairs |
|
Jannie Oosthuizen
President-Merck Human Health |
|
Jennifer Zachary
Executive Vice President & General Counsel |
|
Johanna Herrmann
Vice President-Global Communications |
|
Joseph Romanelli
President-Human Health International |
|
Kathy J. Warden
Independent Director |
|
Kelly E. W. Grez
Secretary |
|
Mary Ellen Coe
Independent Director |
|
Michael Klobuchar
Chief Strategy Officer & Executive Vice President |
|
Pamela J. Craig
Independent Director |
|
Patricia Fiorello Russo
Independent Director |
|
Paul B. Rothman
Independent Director |
|
Peter Dannenbaum
Vice President-Investor Relations |
|
Richard R. DeLuca
Executive Vice President & President-Animal Health |
|
Risa J. Lavizzo-Mourey
Independent Director |
|
Robert M. Davis
Chairman, President & Chief Executive Officer |
|
Sanat Chattopadhyay
EVP & President-Merck Manufacturing Division |
|
Stephen L. Mayo
Independent Director |
|
Sylvia A. Ayler
Legal Director |
|
Thomas Henry Glocer
Lead Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
